This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Theralase Technologies's Median PS Value or its related term are showing as below:
TLTFF'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 1.13 Med: 1.99 Max: 5.75
Current: 2.03
During the past 13 years, the highest Price to Median PS Value of Theralase Technologies was 5.75. The lowest was 1.13. And the median was 1.99.
TLTFF's Price-to-Median-PS-Value is ranked worse than 91.96% of 311
companies
in the Medical Devices & Instruments industry
Industry Median: 0.79
vs TLTFF: 2.03
Theralase Technologies Median PS Value Historical Data
The historical data trend for Theralase Technologies's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Theralase Technologies's Median PS Value
For the Medical Devices subindustry, Theralase Technologies's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies's Price-to-Median-PS-Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's Price-to-Median-PS-Value falls into.
Theralase Technologies Median PS Value Calculation
10-Year Median PS Ratio is 30.
Theralase Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.003.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralase Technologies (OTCPK:TLTFF) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Theralase Technologies's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.183
/
0.09
=
2.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralase Technologies Median PS Value Related Terms
Thank you for viewing the detailed overview of Theralase Technologies's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TLTFF has been successfully added to your 